Resveratrol Inhibits Growth of Orthotopic Pancreatic Tumors through Activation of FOXO Transcription Factors by Roy, Sanjit K. et al.
Resveratrol Inhibits Growth of Orthotopic Pancreatic






2, Rakesh K. Srivastava
1*
1Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City,
Kansas, United States of America, 2Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center,
Kansas City, Kansas, United States of America
Abstract
Background: The forkhead transcription factors of the O class (FOXO) play a direct role in cellular proliferation, oxidative
stress response, and tumorigenesis. The objectives of this study were to examine whether FOXOs regulate antitumor
activities of resveratrol in pancreatic cancer cells in vitro and in vivo.
Methodology/Principal Findings: Pancreatic cancer cell lines were treated with resveratrol. Cell viability, colony formation,
apoptosis and cell cycle were measured by XTT, soft agar, TUNEL and flow cytometry assays, respectively. FOXO nuclear
translocation, DNA binding and transcriptional activities were measured by fluorescence technique, gelshift and luciferase
assay, respectively. Mice were orthotopically implanted with PANC1 cells and orally gavaged with resveratrol. The
components of PI3K and ERK pathways, FOXOs and their target gene expressions were measured by the Western blot
analysis. Resveratrol inhibited cell viability and colony formations, and induced apoptosis through caspase-3 activation in
four pancreatic cancer cell lines (PANC-1, MIA PaCa-2, Hs766T, and AsPC-1). Resveratrol induced cell cycle arrest by up-
regulating the expression of p21/CIP1, p27/KIP1 and inhibiting the expression of cyclin D1. Resveratrol induced apoptosis by
up-regulating Bim and activating caspase-3. Resveratrol inhibited phosphorylation of FOXOs, and enhanced their nuclear
translocation, FOXO-DNA binding and transcriptional activities. The inhibition of PI3K/AKT and MEK/ERK pathways induced
FOXO transcriptional activity and apoptosis. Furthermore, deletion of FOXO genes abrogated resveratrol-induced cell cycle
arrest and apoptosis. Finally, resveratrol-treated mice showed significant inhibition in tumor growth which was associated
with reduced phosphorylation of ERK, PI3K, AKT, FOXO1 and FOXO3a, and induction of apoptosis and FOXO target genes.
Conclusions: These data suggest that inhibition of ERK and AKT pathways act together to activate FOXO transcription
factors which are involved in resveratrol-mediated pancreatic tumor growth suppression.
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Introduction
Cancer of the pancreas is the fourth leading cause of cancer-
related mortality in the United States with a 5-year survival less
than 5% [1]. Pancreatic ductal adenocarcinoma is a highly
aggressive disease that invariably evades early diagnosis [2]. The
mean survival time for patients with metastatic disease is only 3–6
months, and only 20–30% of pancreatic cancer cases are alive
after 12 months. Several factors are associated with increased risk
for pancreatic cancer and these include chronic pancreatitis,
smoking, diabetes, prior gastric surgery, exposure to certain classes
of organic solvents, radiation, and specific gene polymorphisms
[3,4]. Heritable as well as several acquired gene mutations have
been identified in pancreatic tumors [5]. The K-Ras oncogene is
primarily mutated in codon 12 in .90% of pancreatic tumors and
the mutation results in a constitutively active form of ras that can
lead to increased cell proliferation. Mutations in the tumor
suppressor gene p53, the cyclin-dependent kinase inhibitor p16,
and SMAD4, a downstream target of TGFb also exhibit high
mutation frequencies in pancreatic tumors.
Since pancreatic cancer is frequently detected at an advanced
stage, it has limited treatment options and insignificant improve-
ments in tumor regression and overall survival [6]. 5-Fluorouracil
alone or in combination with other drugs has been extensively
used for treatment of advanced pancreatic cancer, and gemcita-
bine, a deoxycytidine analog (or antimetabolite), has partially
replaced 5-fluorouracil as a treatment for pancreatic cancer.
Therefore, effective strategies are urgently needed to prevent
pancreatic cancer. Resveratrol is a polyphenolic phytochemical
that exhibits a broad spectrum of anticancer activities against
multiple tumor types, including pancreatic cancer [7]. In vitro,
resveratrol inhibited the proliferation of human pancreatic cancer
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inhibited the constitutive activation of NFkB and its gene products
[8]. In vivo, resveratrol significantly suppressed the growth of the
tumor and this effect was further enhanced by gemcitabine [8].
Resveratrol also suppressed the NFkB activation and expression of
cyclin D1, COX-2, ICAM-1, MMP-9 and survivin in tumor
tissues [8]. Furthermore, we recently demonstrated that resveratrol
induced apoptosis by activating capase-3/7 and inhibiting the
expression of Bcl-2 and XIAP in human pancreatic cancer stem
cells (CSCs) [9]. Resveratrol inhibited pluripotency maintaining
factors (Nanog, Sox-2, c-Myc and Oct-4) and drug resistance gene
ABCG2 in CSCs. Inhibition of Nanog by shRNA enhanced the
inhibitory effects of resveratrol on self-renewal capacity of CSCs.
Finally, resveratrol inhibited CSC’s migration and invasion and
markers of epithelial-mesenchymal transition (EMT) such as Zeb-
1, Slug and Snail. Overall, resveratrol inhibited pancreatic CSC
characteristics in human and Kras
G12D transgenic mice by
inhibiting pluripotency maintaining factors and EMT.
Transcription factors of the Forkhead box O (FOXO) class are
predominantly regulated through phosphoinositide 3-kinase/AKT
(also known as PKB) pathway. FOXO1a/FKHR, FOXO3a/
FKHRL1, and FOXO4/AFX are members of FOXO subfamily
[10]. The PI3K/AKT pathway phosphorylates all of these FOXO
proteins, resulting in impairment of DNA binding ability and
inhibition of FOXO-dependent transcription [11]. Inhibition of
the PI3K/AKT pathway leads to dephosphorylation and nuclear
translocation of active FOXOs, which causes cell cycle arrest and
apoptosis [12]. Conversely, loss of PTEN activity results in
increased AKT activity leading to inhibition of FOXO activity
through phosphorylation and cytoplasmic sequestration [12].
FOXO transcriptional activity controls cellular proliferation and
apoptosis downstream of PTEN, PI3K and AKT [13]. Since
inactivation and loss of PTEN, and overexpression of AKT are
frequently observed in pancreatic cancer [14], targeting a
downstream target such as FOXO may be an attractive idea for
pancreatic cancer prevention and/or treatment.
In addition to PI3K/AKT, MAP kinase pathway has also been
shown to regulate FOXO activities. The Ras proteins transduce
signals from ligand-activated tyrosine kinase receptors to down-
stream effectors which can lead to cellular transformation [15,16].
Constitutive activation of the Ras-ERK/MAPK signaling pathway
often leads to promotion of abnormal cell growth and tumorigen-
esis [17]. In mammalian cells, ERK [18], p38 MAP kinase [19],
and JNK [20,21] regulate mitosis, movement, metabolism and
apoptosis. These MAP kinases are activated by the dual
phosphorylations of neighboring threonine and tyrosine residues
in response to various extracellular stimuli [22]. Specifically, ERKs
are often activated by growth signals [23], whereas p38 and JNK
are activated by stress-responsive signal [20]. Activation of ERK
leads to phosphorylation and inactivation of FOXO proteins.
Since FOXO proteins can be phosphorylated by AKT and ERK,
inhibition of these pathways could be considered as a novel
strategy for the prevention and/or treatment of pancreatic cancer.
In support of this hypothesis, we have recently demonstrated that
inhibition of PI3K/AKT and MEK/ERK pathways act synergis-
tically to regulate anti-angiogenic effects of EGCG and sulforaph-
ane through activation of FOXO transcription factors and
downstream target genes [24,25].
Although resveratrol has been shown to inhibit pancreatic
cancer cell growth, its effects on the regulation of FOXO
transcription factors and downstream targets in pancreatic cancer
have never been examined. Furthermore, resveratrol, which
simultaneously inhibits the activation of PI3K/AKT and MEK/
ERK pathways (resulting in activation of FOXO), could be an
attractive candidate for the management of pancreatic cancer.
The objectives of our study were to examine the molecular
mechanisms by which resveratrol inhibits pancreatic cancer
growth in vitro and in vivo. Our results demonstrate that
resveratrol induced the expression of PTEN, phosphorylation of
JNK and p38, and inhibited phosphorylation of PI3K, AKT,
ERK, FOXO1 and FOXO3a leading to growth arrest and
apoptosis. Furthermore, inhibition of FOXOs by shRNA blocked
anti-proliferative and proapoptotic effects of resveratrol. Finally,
resveratrol-treated mice showed significant inhibition in tumor
growth which was associated with reduced phosphorylation of
ERK, PI3K, AKT, FOXO1 and FOXO3a, and induction of
apoptosis and FOXO target genes in tumor tissues.
Results
Inhibition of pancreatic cancer cell viability and colony
formation by resveratrol
We first examined the effects of resveratrol on cell viability of
four pancreatic cancer cell lines by XTT assay. These four
pancreatic cancer cell lines (MIA PaCa-2, AsPC-1, PANC-1 and
Hs766T) were selected due to their different genetic background
and pathological stages. As shown in Fig. 1A, resveratrol inhibited
cell viability in a dose-dependent manner. PANC-1 and MIA
PaCa-2 cell lines were most sensitive, AsPC-1 cell line was
moderately sensitive, and Hs 766T cell line was least sensitive.
These data demonstrate the anti-proliferative effects of resveratrol
on human pancreatic cancer cells.
We next examined the effects of resveratrol on colony formation
on four pancreatic cancer cell lines by soft agar assay. Resveratrol
inhibited colony formation in a dose-dependent manner (Fig. 1B).
Colonies formed by PANC-1 and MIA PaCa-2 cells were most
sensitive, AsPC-1 cell line was moderately sensitive, and Hs 766T
cell line was least sensitive. These data suggest that resveratrol can
be used as a potent chemopreventive/therapeutic agent for
pancreatic cancer.
Mitochondria play a major role in apoptosis which can be
induced by active caspase-3 [26]. We therefore examined whether
resveratrol induces apoptosis through activation of caspase-3 in
pancreatic cancer cell lines (Fig. 1C). Resveratrol induced caspase-
3 activity in PANC-1, MIA PaCa-2, Hs 766T and AsPC-1 cells.
However, the activation of caspase-3 was less in Hs766T cells
compared to other pancreatic cancer cell lines. These data suggest
that resveratrol induces apoptosis through activation of caspase-3
in pancreatic cancer cells.
Regulation of apoptosis and cell cycle proteins in
pancreatic cancer cells by resveratrol
We next examined the effects of resveratrol on apoptosis
(Fig. 2A). Resveratrol induced apoptosis in PANC-1, MIA PaCa-2,
HS766T and AsPC-1 cells in a dose-dependent manner. PANC-1
and MIA PaCa-2 cell lines were most sensitive, AsPC-1 cell line
was moderately sensitive, and Hs 766T cell line was least sensitive.
These data suggest that resveratrol can induce apoptosis in
pancreatic cancer cells irrespective of their Kras status, and thus
can be used as a cancer preventive agent.
PI3K/AKT signaling pathway has been shown to regulate cell
cycle progression through regulation of FOXO transcription
factors [27]. We therefore examined the effects of FOXO
transcription factors on resveratrol-induced cell cycle arrest by
inhibiting the FOXO transcription factors by shRNA (Fig. 2B).
FOXO1/FOXO3a/FOXO4 shRNA expression vectors have
been described elsewhere [28]. Treatment of PANC-1/scrambled
cells with resveratrol resulted in cell cycle arrest at G1 stage
FOXO-Dependent Regulation of Tumorigenesis
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25166(Control=48.1%, resveratrol=83.6%). By comparison, inhibition
of FOXO1/FOXO3a/FOXO4 by shRNA blocked resveratrol-
induced growth arrest. These data suggest that FOXO transcrip-
tion factors are required for resveratrol-induced cell cycle arrest.
We next examined the effects of resveratrol on FOXO target
genes (Fig. 2C). Resveratrol inhibited the expression of cyclin D1
and induced the expression of cell cycle inhibitors (p21/CIP1 and
p27/KIP1) and Bim in PANC-1 cells. Over all, these data suggest
that resveratrol causes growth arrest and induces apoptosis
through regulation of FOXO target genes such as cyclin D1,
p21/CIP1, p27/KIP1 and Bim.
Inhibition of PI3K/AKT and MAP kinase pathways
enhance resveratrol-induced apoptosis
The constitutively AKT has been shown to enhance survival of
cancer cells and also to be the cause of drug-resistance [29]. Since
PTEN regulates AKT activity, we measured the expression of
PTEN and phosphorylation status of AKT in pancreatic cancer
cells treated with resveratrol (Fig. 3A). Resveratrol induces PTEN
expression and inhibits AKT phosphorylation in PANC-1 cells. By
comparison, resveratrol has no effect on total AKT expression. We
next confirmed the inhibition of AKT activation by resveratrol
with kinase assay (Fig. 3B). Resveratrol inhibited AKT kinase
activity in a dose-dependent manner. These data suggest that
resveratrol inhibits cell proliferation by regulating PI3K/AKT
pathway.
Ras/Raf/MAP kinase pathway has been shown to regulate
migration, mitosis, metabolism, and apoptosis [20]. We therefore
examined the effects of resveratrol on the expression of Ras, and
activation of ERK, JNK and p38 MAP kinases. Resveratrol
inhibited Ras expression in PANC-1 cells (Fig. 3A). Treatment of
PANC-1 cells with resveratrol caused a decrease in ERK
phosphorylation, and an increase in JNK phosphorylation. By
comparison, treatment of PANC-1 cells with resveratrol resulted in
a slight increase in the phosphorylation of p38 MAP kinase. These
data suggest that resveratrol inhibits growth and induces apoptosis
through regulation of Ras/Raf/MAP kinase pathway.
PI3K/AKT pathway has been shown to inhibit apoptosis. We
next examined whether resveratrol induces apoptosis through
PI3K/AKT pathway (Fig. 3C). Pancreatic cancer cells were
transfected with empty vector, wild type PTEN, dominant
negative AKT (DN-AKT), and apoptosis was measured. Overex-
pression of wild type PTEN or DN-AKT induced apoptosis in
AsPC-1 and PANC-1 cells. Treatment of these transfected cells
Figure 1. Effects of resveratrol on cell viability, colony formation and caspase-3 activity in pancreatic cancer cells. (A), Cell Viability.
Pancreatic cancer (PANC-1, MIA PaCa-2, Hs766T and AsPC-1) cells were treated with resveratrol (0–30 mM) for 48 h. Cell viability was measured by XTT
assay. Data represent the mean 6 S.D. *=significantly different from respective controls, P,0.05. (B), Colony formation. Pancreatic cancer (PANC-1,
MIA PaCa-2, Hs766T and AsPC-1) cells were treated with resveratrol (0–30 mM) for 3 weeks. At the end of incubation period, colonies were fixed and
number of colonies were counted. Data represent the mean 6 S.D. *=significantly different from respective controls, P,0.05. (C), Caspase-3 activity.
Pancreatic cancer PANC-1, MIA PaCa-2, Hs 766T and AsPC-1 cells were treated with resveratrol (0–40 mM) for 24 h and caspase-3 activity was
measured as per manufacturer’s instructions (EMD Biosciences). Data represent the mean 6 S.D. *=significantly different from respective controls,
P,0.05.
doi:10.1371/journal.pone.0025166.g001
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that inhibition of PI3K/AKT pathway enhances resveratrol-
induced apoptosis in pancreatic cancer cells.
Since inhibition of PI3K/AKT and MEK/ERK pathways
together induce apoptosis in an additive or synergistic manner, we
sought to examine whether these pathways act together to regulate
resveratrol-induced apoptosis. The activations of AKT and MEK/
ERK were inhibited by AKT Inh-IV and PD98059, respectively.
AKT inhibitor (AKT Inh-IV) and MEK1/2 inhibitor (PD98059)
alone induced apoptosis in both PANC-1 and AsPC-1 cells
(Fig. 3D). AKT inhibitor and MEK1/2 inhibitor (PD98059)
synergistically/additively induced apoptosis in PANC-1 and
AsPC-1 cells. Interestingly, the combination of AKT inhibitor
and PD98059 with resveratrol induced more apoptosis than AKT
inhibitor plus resveratrol or PD98059 plus resveratrol. Based on
these data, it can be suggested that the inhibition of PI3K/AKT
and MEK/ERK pathways act together to enhance resveratrol-
induced apoptosis.
FOXO transcription factors regulate resveratrol-induced
apoptosis in pancreatic cancer cells
Inhibition of PI3K/AKT and MEK/ERK pathways activates
FOXO transcription factors. We therefore examined whether
FOXO transcription factors regulate apoptosis induced by
resveratrol in pancreatic cancer cells. PANC-1 and AsPC-1 cells
were transfected with FOXO1-WT, FOXO1-TM (phosphoryla-
tion mutant), FOXO3a or FOXO3a-TM (phosphorylation
deficient mutant) (Fig. 4A and B). Wild type and phosphorylation
deficient mutants of FOXO expression plasmids have previously
been described [24]. Overexpression of FOXO1, FOXO1-TM,
FOXO3a and FOXO3a-TM induced apoptosis in both PANC-1
and AsPC-1 cells. However, phosphorylation deficient mutants of
FOXO1 and FOXO3a induced more apoptosis than wild type
FOXO1 and FOXO3a. Resveratrol also induced apoptosis in
both PANC-1 and AsPC-1 cells. Overexpression of FOXO1-WT,
FOXO1-TM, FOXO3a or FOXO3a-TM further enhanced
resveratrol-induced apoptosis. Phosphorylation deficient mutants
of FOXO1 and FOXO3a had more effects on resveratrol-induced
apoptosis than wild type counterparts. These data suggest that the
phosphorylation of FOXO transcription factors plays a major role
in their activities, and FOXO (wild type and triple mutant) can
enhance resveratrol-induced apoptosis.
We next examined whether inhibition of FOXO transcription
factors by shRNA abolishes resveratrol-induced apoptosis (Fig. 4C
and D). Pancreatic cancer PANC-1 and MIA PaCa-2 cells were
stably transfected with plasmids expressing FOXO1, FOXO3a
and FOXO4 shRNA. These expression vectors have been
described elsewhere [28]. Resveratrol induced apoptosis in
PANC-1 and MIA PaCa-2 cells transfected with scrambled
vectors. By comparison, inhibition of FOXO1, FOXO3a and
FOXO4 through shRNA inhibited resveratrol induced apoptosis
in PANC-1 and MIA PaCa-2 cells. These data suggest that FOXO
Figure 2. Effect of resveratrol on apoptosis and cell cycle. (A), Pancreatic cancer PANC-1, MIA PaCa-2, Hs 766T and AsPC-1 cells were treated
with resveratrol (0–30 mM) for 48 h and apoptosis was measured by TUNEL assay. Data represent the mean 6 S.D. *=significantly different from
respective controls, P,0.05. (B), PANC-1 cells were transfected with either scrambled or FOXO1/FOXO3a/FOXO4 shRNA expressing constructs and
treated with resveratrol (10 mM) for 24 h. At the end of incubation period, cells were harvested, and cell cycle analysis was performed by flow
cytometry. (C), Effects of resveratrol on cell cycle regulatory genes. PANC-1 cells were treated with resveratrol (0–20 mM) for 24 h. The expression of
cyclin D1, p21
/CIP1, p27
/KIP1 and Bim was measured by Western blotting. Anti b-actin antibody was used as a loading control.
doi:10.1371/journal.pone.0025166.g002
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apoptosis by resveratrol.
Inhibition of PI3K/AKT and MEK/ERK pathways or
overexpression of FOXO transcription factor
synergistically induces FOXO transcriptional activity in
the presence or absence of resveratrol
Since inhibition of PI3K/AKT and MEK/ERK pathways
synergistically induces apoptosis in pancreatic cancer cells, we next
sought to examine whether inhibition of these two pathways act
together to regulate FOXO activity. FOXO-luciferase construct
(pGL3-6X DBE) have previously been described [24]. AKT
inhibitor (AKT Inh-IV) and MEK1/2 inhibitor (PD98059)
synergistically induced FOXO transcriptional activity in AsPC-1
and PANC-1 cells (Fig. 5A). AKT Inh-IV or PD98059 enhanced
resveratrol-induced FOXO transcriptional activity. Interestingly,
the combination of AKT Inh-IV and PD98059 with resveratrol-
induced higher FOXO transcriptional activity than AKT Inh-IV
plus resveratrol or PD98059 plus resveratrol. These data suggest
that inhibition of PI3K/AKT and MEK/ERK pathways acts
synergistically/additively to regulate FOXO transcriptional activ-
ity in the absence or presence of resveratrol.
Since inhibition of FOXO1 (FKHR) transcription factor
enhanced resveratrol-induced apoptosis in pancreatic cancer cells,
we sought to examine whether resveratrol enhances translocation
of wild type and phosphorylation deficient mutant of FOXO1 to
nucleus (Fig. 5B). PANC-1 cells were transfected with GFP-
FOXO1 or GFP-FOXO1-TM plasmids and treated with
resveratrol. The translocation of FOXO1 to nucleus was measured
by fluorescence microscopy. Resveratrol induced translocation of
FOXO1 to nucleus. However, the translocation of phosphoryla-
tion deficient mutant of FOXO1 was much higher than wild type
FOXO1. These data suggest that resveratrol can regulate
translocation of FOXO transcription factor to the nucleus.
We next examined whether resveratrol induces transcriptional
activation of FOXO in the presence or absence phosphorylation
deficient triple mutants of FOXO proteins (FOXO1-TM,
Figure 3. Effects of resveratrol on the expression of PTEN, AKT and MAP kinases; and the effects of PI3K/AKT and MAPK pathways
on resveratrol-induced apoptosis. (A), PANC-1 cells were treated with or without resveratrol (0–20 mM) for 24 h. The cells were harvested and the
expression of PTEN, phospho-AKT, AKT, Ras, phospho-ERK, ERK, phospho-JNK, JNK, phospho-p38 and p38 was measured by Western blotting. (B), AKT
kinase activity. PANC-1 cells were treated with resveratrol (0–20 mM) for 24 h. AKT kinase activity was measured as we described in materials and
methods. Data represent the mean 6 S.D. *, #, %, and @=significantly different from respective controls, P,0.05. (C), PTEN and dominant negative
AKT enhance resveratrol-induced apoptosis. PANC-1 and AsPC-1 cells were transiently transfected with empty vector (pcDNA3.1), PTEN wild type
(PTEN-WT) or dominant negative AKT (AKT-DN) along with pCMV-LacZ vector (as transfection control) for 24 h. After medium replacement, cells were
treated with resveratrol (10 mM) for 48 h and, apoptosis was measured by TUNEL assay. Data represent the mean 6 S.D. * and #=significantly
different from respective controls, P,0.05. (D), PANC-1 and AsPC-1 cells were pretreated with AKT inhibitor IV (1 mM) and/or MEK1/2 inhibitor
PD98059 (10 mM) for 2 h, followed by treatment with or without resveratrol (10 mM) for 48 h. At the end of incubation period, cells were harvested
and apoptosis was measured by TUNEL assay. Data represent mean 6 SD. *, ** and #=significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0025166.g003
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cells were transfected with wild type FOXO promoter linked to a
luciferase reporter gene in the presence or absence of plasmids
expressing FOXO1-TM, FOXO3a-TM, or FOXO4-TM. After
transfection, cells were treated with resveratrol for 24 h, and
luciferase activity was measured. Transfection of cells with
plasmids expressing FOXO1-TM, FOXO3a-TM, or FOXO4-
TM induced FOXO transcriptional activity compared with the
empty vector (control). Resveratrol also induced FOXO tran-
scriptional activity. Interestingly, resveratrol-induced FOXO
transcriptional activity was further enhanced in the presence of
FOXO1-TM, FOXO3a-TM, and FOXO4-TM. These data
indicate that FOXO transcription factor may play a major role
in mediating biological effects of resveratrol in pancreatic cancer
cells.
Since resveratrol induces apoptosis and FOXO transcriptional
activity, we next sought to examine the effects of resveratrol on
phosphorylation of FOXO1 and FOXO3a in the cytoplasmic
fractions (Fig. 5D, left Panel). Resveratrol inhibited the phosphor-
ylation of FOXO1 and FOXO3a in PANC-1 cells. Since
resveratrol inhibited the phosphorylation of FOXO1 and
FOXO3a and enhanced the nuclear translocation of wild type
and mutant FOXO1-TM, we next sought to examine the FOXO-
DNA binding activity by gelshift assay (Fig. 5D, right panel).
Treatment of PANC-1 cells with resveratrol resulted in enhanced
FOXO-DNA binding activity reaching maximum at 24 h. The
FOXO-DNA binding in the presence of SP1 (lysate from
untreated cells) was similar to untreated control. Overall, these
data suggest that resveratrol can inhibit the phosphorylation of
FOXO transcription factors, leading to their translocation to
nucleus and enhanced FOXO transcriptional activity.
Resveratrol inhibits the expression of Sirt1, Sirt2 and Sirt3
in pancreatic cancer cells
Since Sirts regulate tumor formation and angiogenesis, we next
examined the effects of resveratrol on the expression of Sirt1, Sirt2
and Sirt3 in pancreatic cancer cells by q-RT-PCR. Resveratrol
inhibited the expression of Sirt1, Sirt2 and Sirt3 in PANC-1, MIA
PaCa-2 and AsPC-1 cells (Fig. 6). These data suggest that anti-
proliferative effects of resveratrol may be exerted through Sirts.
Resveratrol inhibits the growth of PANC-1 cells
orthotopically implanted in Balb C Nude mice by
inhibiting FOXO transcription factors
We next validated our in vitro data that resveratrol inhibits
growth of pancreatic cancer cells by inhibiting ERK and PI3K/
AKT pathways leading to activation of FOXO transcription
factors. PANC-1 cells were orthotopically implanted in Balb C
nude mice and treated with resveratrol (0–60 mg/kg body weight)
through gavage (Monday to Friday, once daily) for 6 weeks. As
shown in Fig. 7A, resveratrol inhibited pancreatic tumor growth in
Balb C nude mice in a dose-dependent manner. Furthermore,
resveratrol has no effect on the body weight of tumor bearing
mice, although mice gained weight during the treatment.
We next examined the effects of resveratrol on apoptosis and
cell proliferation in tumor tissues derived from control and
resveratrol treated mice (Fig. 7B). Resveratrol induced apoptosis
and inhibited cell proliferation in tumor tissues in a dose-
dependent manner. Since resveratrol induced apoptosis and
inhibited cell proliferation, we next sought to examine the
molecular mechanisms of the effects of resveratrol. Resveratrol
induced the expression of Bim, p27/KIP1 and p21/CIP1, cleaved
caspase-3, and inhibited the expression of PCNA (Fig. 7C). Since
ERK and AKT phosphorylates FOXO, we next sought to
examine the effects of resveratrol on the dephosphorylation/
activation FOXOs. Western blot analyses were performed to
examine the expression of p-ERK, ERK, p-PI3K (Tyr458), PI3K,
p-AKT (Ser473), AKT, p-FOXO (Ser256), FOXO, p-FOXO3a
(Ser253), and FOXO3a. As shown in Fig. 7D, resveratrol inhibited
the phosphorylation of ERK, PI3K (Tyr458), p-AKT (Ser473), p-
FOXO (Ser256) and p-FOXO3a (Ser253). It has no significant
effect on the expression of total proteins. These data confirm our
Figure 4. Effects of FOXO transcription factors on resveratrol induced apoptosis. (A and B), Phosphorylation deficient mutants of FOXO
enhance resveratrol-induced apoptosis in pancreatic cancer cells. PANC-1 and AsPC-1 cells were transiently transfected with empty vector or plasmids
encoding FOXO1-TM, FOXO3a-TM, or FOXO4-TM for 24 h. After transfection, culture medium was replaced with complete RPMI medium and treated
with resveratrol (10 mM) for 48 h. Apoptosis was measured by TUNEL assay. Data represent the mean 6 S.D. *, #, **, =significantly different from
control, P,0.05. (C and D), PANC-1 and MIA PaCa-2 cells were stably transfected with either scrambled or FOXO1, FOXO3a and FOXO4 shRNA
plasmids. Transfected cells were treated with resveratrol (10 mM) and apoptosis was measured by TUNEL assay. Data represent the mean 6 S.D. *,
#=significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0025166.g004
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by inhibiting ERK and PI3K/AKT pathways in pancreatic cancer
cells.
Discussion
In this paper we have demonstrated, for the first time, that
polyphenolic compound resveratrol causes growth arrest and
induces apoptosis through activation of FOXO transcription
factors. Resveratrol induces apoptosis through caspase-3 activa-
tion, and causes growth arrest through induction of p21 and p27
and inhibition of cyclin D1 which are the downstream targets of
FOXO. Inhibition of PI3K/AKT and MEK/ERK pathways acts
together to enhance the activation of FOXO transcriptional
activity, and phosphorylation deficient triple mutants of FOXO
further enhance resveratrol-induced FOXO activity and apopto-
sis. Inhibition of FOXO1, FOXO3a and FOXO4 by shRNA
blocked resveratrol-induced cell cycle arrest and apoptosis.
Resveratrol-induced suppression of PANC1 tumor growth in
nude mice was associated with inhibition of ERK, PI3K, AKT,
FOXO1 and FOXO3a phosphorylation, and induction of
apoptosis in tumor tissues. Resveratrol also induced the expression
Figure 5. Inhibition of PI3K/AKT and MEK/ERK pathways synergistically/additively enhanced resveratrol -induced apoptosis and
FOXO transcriptional activity in pancreatic cancer cells. (A), PANC-1 and AsPC-1 cells were transiently transfected with 66 DBE-luciferase
construct for 24 h. After transfection, cells were pretreated with AKT inhibitor IV (1 mM) and/or MEK1/2 inhibitor PD98059 (10 mM) for 2 h, followed by
treatment with or without resveratrol (10 mM) for 24 h. Cells were harvested for firefly/Renilla luciferase assays using the Dual-Luciferase Reporter
Assay System (Promega). Luciferase counts were normalized using Renilla luciferase transfection control (pRL-TK; Promega). Data represent the mean
6 S.D. *, # and **=significantly different from respective controls, P,0.05. (B), Resveratrol induces translocation of wild type and triple mutant
FOXO1 to nucleus. Pancreatic cancer PANC-1 cells were transfected with either GFP-FOXO1 or GFP-FOXO-TM and treated with resveratrol (10 mM) for
24 h. Cells were visualized by fluorescence microscopy. (C), Phosphorylation deficient mutants of FOXO (triple mutants) enhance resveratrol-induced
FOXO transcriptional activity in pancreatic cancer. PANC-1 and AsPC-1 cells were transiently transfected with empty vector or constructs encoding
FOXO1-TM, FOXO3a-TM, or FOXO4-TM together with 66DBE-luciferase for 24 h. After transfection, culture medium was replaced with complete
RPMI, treated with resveratrol (10 mM) for 24 h, and harvested for firefly/Renilla luciferase assays using the Dual-Luciferase Reporter Assay System
(Promega). Luciferase counts were normalized using Renilla luciferase transfection control (pRL-TK; Promega). Data represent the mean 6 S.D. *, %
and #=significantly different from control, P,0.05. (D) Left panel, Resveratrol inhibits cytoplasmic phosphorylation of FOXO1 and FOXO3a. PANC-1
cells were treated with resveratrol (0, 10 and 20 mM) for 36 h, and cytoplasmic fractions were prepared. The expressions of p-FOXO1 and p-FOXO3a
were measured by the Western blot analysis. Right Panel, FOXO-DNA binding. PANC-1 cells were treated with or without resveratrol (10 mM) for
various time points (0–32 h). Nuclear extracts were prepared. Gelshift assay was performed as we described in Material and Methods. Lane 1=probe
only, lane 2=506 cold probe, lane 3=control, lane 4=cell lysates from control samples treated with SP1 probe, lanes 5–11=cell lysate from
resveratrol treated samples at 4, 8, 12, 16, 20, 24 and 32 h.
doi:10.1371/journal.pone.0025166.g005
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pancreatic tumor tissues. Similarly, others have also demonstrated
the antiproliferative and proapoptotic effects of resveratrol in
pancreatic cancer [30,31], and here we further added the role of
FOXO transcription factors in mediating the effects of resveratrol.
Since resveratrol is a nontoxic polyphenolic compound, it can be
safely used for the treatment and/or prevention of pancreatic
cancer.
Resveratrol exerts its anticancer and chemopreventive proper-
ties against various types of cancer [32]. Some of the beneficial
effects of resveratrol may be due to its ability to suppress
autophagy by targeting p70 S6 kinase (S6K1) [33]. Resveratrol
suppresses proliferation of various types of cancer cells, including
breast, lung, pancreas, liver, stomach, prostate, colon, leukemia,
and medulloblastoma [7]. Antitumor activities of resveratrol have
also been demonstrated in several mouse models of cancer [7],
although the precise mechanisms and pathways involved remain
unclear. In the present study, we have discovered a new
mechanism by which resveratrol inhibits pancreatic tumor growth
i.e. activation of FOXO transcription factors.
FOXO transcription factors have been shown to regulate tissue
homeostasis in the pancreas, diabetes and cancer. In recent years,
they have emerged as critical transcriptional integrators among
pathways regulating proliferation, survival, differentiation and
angiogenesis. FOXO regulates apoptotic and cell cycle genes such
as Bim [28], Fas ligand [34], p27/KIP1 [28], and Bcl-6 [35]. Our
results show that resveratrol induced the expression of PTEN and
inhibited the phosphorylation/activation of AKT in PANC-1 cells.
We also demonstrate that the inhibition of AKT phosphorylation
is correlated with the activation of FOXO transcription factors
and induction of Bim, p21
/CIP1 and p27
/KIP1. In vivo, resveratrol
also induced the expression of FOXO target genes such as Bim,
p27/KIP1 and p21/CIP1 in pancreatic tumor tissues. In other
studies, we have demonstrated that anti-angiogenic effects of
chemopreventive agents EGCG, resveratrol and sulforaphane are
mediated through activation of FOXO transcription factors
[25,36]. Together, these studies suggest that activation of FOXO
transcription factors by chemopreventive agents may regulate cell
cycle, apoptosis and angiogenesis.
The PI3K/AKT and MAPK pathways can be activated by
Kras [24,25,37]. AKT and ERK both have been shown to
directly phosphorylate and inactivate FOXO transcription
factors, resulting in cytoplasmic retention, inactivation, and
inhibition of the expression of FOXO-regulated genes, which
control various processes such as metabolism, cell cycle, cell death
and oxidative stress [38]. Our results show that resveratrol
inhibited cytoplasmic phosphorylation of FOXOs, and enhanced
FOXO nuclear translocation, FOXO-DNA binding and tran-
scriptional activities. The inhibition of PI3K/AKT and MEK/
ERK pathways induced FOXO transcriptional activity and
apoptosis. Overexpression of phosphorylation deficient triple
mutants of FOXOs induced FOXO activity, and further
enhanced resveratrol-induced FOXO activity and apoptosis,
whereas deletion of FOXOs genes by shRNA abrogated
resveratrol-induced cell cycle arrest and apoptosis. Resveratrol-
induced suppression of tumor growth in mice was associated with
inhibition of ERK and PI3K/AKT pathway and activation of
FOXO1 and FOXO3a. Taken together, these studies demon-
strate that the activation of FOXOs has significant implication for
the treatment and prevention of pancreatic cancer, where Kras is
activated in about 90% patients, and PI3K/AKT and MEK/
ERK pathways are highly activated.
In addition to phosphorylation, the regulation of FOXO
transcription factors by acetylation has also been demonstrated.
The acetylation/deacetylation of FOXO can be regulated by
p300, Cbp (CREB-binding protein) and Pcaf (p300/CBP-
associated factors) in response to oxidative stress or DNA binding,
followed by deacetylation by class I and II histone deacetylases
[39], including Sirt1 [40]. Many of the SIRT1 substrates are
transcription factors and key regulators described to take part in
cancer development, such as the NFkB, the DNA repair factor
Ku70, the tumor suppressor gene p53, and the FOXOs. The
relationship between tumorigenesis and SIRT1 activity is still open
to debate. Although some studies have suggested that SIRT1 may
function as a tumor promoter because of its increased expression
in some types of cancers, other studies have demonstrated that
SIRT1 levels are reduced in some other types of cancers thereby
acting as tumor suppressors. With an improved SIRT1 deacetyla-
tion assay, it has been reported that polyphenolic stimulators
Epigallocatechin galate (EGCG), epicatechin galate (ECG) and
myricetin stimulated SIRT1 under stabilizing conditions, whereas
without stabilization, these polyphenols strongly inhibited SIRT1,
probably due to H2O2 formation [41]. In the present study,
resveratrol inhibited the expression of SIRT1, SIRT2 and SIRT3
Figure 6. Inhibtion of Sirts by resveratrol in pancreatic cancer
cells. (A–C) Pancreatic cancer PANC-1, MIA PaCa-2 and AsPC-1 cells
were treated with resveratrol (0–30 mM) for 24 h, and the expression of
Sirt1, Sirt2 and Sirt3 was measured by qRT-PCR. Data represent mean 6
SD. *=significantly different from respective control, P,0.05.
doi:10.1371/journal.pone.0025166.g006
FOXO-Dependent Regulation of Tumorigenesis
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25166in pancreatic cancer cells, thus suggesting a role of SIRT1 as a
tumor suppressor in cancer cells.
However, further studies are needed to examine the conse-
quences of acetylation/deacetylation of FOXO transcription
factors on tumorigenesis and angiogenesis.
In summary, we have demonstrated that resveratrol induces cell
cycle arrest and apoptosis through regulation of FOXO
transcription factors. Pharmacological and genetic inhibitions of
PI3K/AKT and MEK/ERK pathways can have synergistic
effects on the activation of FOXO transcription factors through
dephosphorylation and nuclear retention, resulting in regulation of
FOXO-target genes. Our study provides important information
regarding the mechanisms by which resveratrol regulates cell
cycle, apoptosis and tumor growth through activation of FOXO
transcription factors. Thus, our studies suggest that inhibition of
ERK and AKT pathways act together to activate FOXO
transcription factors which are involved in resveratrol-mediated
pancreatic tumor growth suppression.
Methods
Ethics Statement
All experiments involving animals were approved by the
Institutional Animal Care and Use Committee (IACUC) of the
University of Texas Health Science Center at Tyler, protocol #
373.
Reagents
Antibodies against PTEN, phospho-AKT, AKT, ras, phospho-
ERK, ERK, phospho-p38, p38, p21/CIP1, p27/KIP1, cyclin D1,
p-FOXO1, FOXO, pFOXO3a, FOXO3a, Bim, PCNA, caspase-
3, and b-actin were purchased from Cell Signaling Technology,
Inc. (Danvers, MA). Enhanced chemiluminescence (ECL) Western
blot detection reagents were from Amersham Life Sciences Inc.
(Arlington Heights, IL). Terminal Deoxynucleotidyl Transferase
Biotin-dUTP Nick End Labeling (TUNEL) assay kit was
purchased from EMD Biosciences/Calbiochem (San Diego, CA).
Resveratrol was purchased from LKT Laboratories, Inc. (St. Paul,
MN). Kits for Terminal Deoxynucleotidyl Transferase Biotin-
dUTP Nick End Labeling (TUNEL) and caspase-3 assays were
purchased from EMD Biosciences/Calbiochem (San Diego, CA).
Cell Culture
PANC-1, MIA PaCa-2, AsPC-1 and Hs 766T cells were
obtained from the American Type Culture Collection (Manassas,
VA) and cultured in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic-antimycotic (Invitrogen) at
37uC in a humidified atmosphere of 95% air and 5% CO2.
Transient Transfection
Cells were plated in 60-mm dishes in RPMI 1640 containing
10% FBS and 1% penicillin-streptomycin mixture at a density of
1610
6 cells/dish. The next day transfections were performed
using LipofectAMINE (Invitrogen Life Technologies, Carlsbad,
CA). Cells were transfected with expression constructs encoding
wild type PTEN (pSG5L-HA-PTENwt), mutant PTEN (pSG5L-
HA-PTEN-G 129E and pSGL5-HA-PTEN-G 129R), wild type-
AKT (pUSE-WT-AKT), constitutively active-AKT (pUSE-CA-
AKT), dominant negative-AKT (pUSE-DN-AKT), or the corre-
sponding empty vectors (pSG5L or pUSE ) in the presence of an
Figure 7. Resveratrol inhibits the growth of PANC-1 tumors orthotopically inplanted in Balb C Nude mice by inhibiting FOXO
transcription factors. (A) Upper Panel, PANC-1 cells were orthotopically implanted into the pancreas of Balb C nude mice. Tumor bearing mice
were treated with resveratrol (0–60 mg/kg body weight) through gavage (Monday to Friday, once daily) for 6 weeks. At the end of the experiment,
pancreatic tumor weights were recorded. Data represent the mean 6 S.D. *, #, %=significantly different from control, P,0.05. Lower Panel, Body
weight of tumor-bearing mice during the experiment. Data represent the mean 6 S.D. (B), Effects of resveratrol on apoptosis and cell proliferation in
tumor tissues. Immunohistochemistry was performed in tumor tissues isolated from control and resveratrol treated mice. Apoptosis was measured by
TUNEL assay and cell proliferation was measured by Ki67 staining. Data represent the mean 6 S.D. *, #, %=significantly different from control,
P,0.05. (C), Effects of resveratrol on markers of apoptosis and cell cycle in tumor tissues. Western blot analyses were performed to examine the
expression of Bim, caspase-3, PCNA, cell cycle inhibitors p27 and p21. The b-actin was used as a loading control. (D), Effects of resveratrol on ERK,
PI3K/AKT and FOXO proteins isolated from tumor tissues. Western blot analyses were performed to examine the expression of p-ERK, ERK, p-PI3K
(Tyr458), PI3K, p-AKT (Ser473), AKT, p-FOXO (Ser256), FOXO, p-FOXO3a (Ser253), and FOXO3a. The b-actin was used as a loading control.
doi:10.1371/journal.pone.0025166.g007
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expressing b-galactosidase. For each transfection, 2 mg of DNA
was diluted into 50 ml of medium without serum. After the
addition of 3 ml of LipofectAMINE into 50 ml Opti-MEM
medium, the transfection mixture was incubated for 10 min at
room temperature. Cells were washed with serum-free medium,
the transfection mixture was added, and cultures were incubated
for 24 hrs in the incubator. The next day, culture medium was
replaced with fresh RPMI 1640 containing 10% FBS and 1%
penicillin-streptomycin mixture and resveratrol was added for
desired times for the measurement of apoptosis and protein
expression.
Western Blot Analysis
Western blots were performed as we described earlier [42]. In
brief, cells were lysed in a buffer containing 10 mM Tris-HCl
(pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1%
SDS, 1 mM sodium orthovanadate, and a mixture of protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepsta-
tin A, 2 mg/ml aprotinin). Lysates were sonicated for 10 s,
centrifuged for 20 min at 10,0006g and stored at 270uC. Equal
amounts of lysate proteins were run on 10% SDS-PAGE and
electrophoretically transferred to nitrocellulose. Nitrocellulose
blots were blocked with 6% nonfat dry milk in TBS buffer
(20 mM Tris-HCl (pH 7.4), and 500 mM NaCl), and incubated
with primary antibody in TBS containing 1% bovine serum
albumin overnight at 4uC. Immunoblots were washed three times
(15, 5 and 5 min each) with TBST (TBS and 0.01% Tween 20).
Immunoreactivity was detected by sequential incubation with
horseradish peroxidase-conjugated secondary antibody and ECL
reagents.
Measurement of Apoptosis
Cells were treated with resveratrol and apoptosis was measured




4 per well) were seeded in a 96-well plate with 200 ml
culture medium. Approximately 16 h later, cells were treated with
various doses of resveratrol to induce apoptosis. Casapse-3 activity
was measured by a fluorometer as per manufacturer’s instructions
(EMD Biosciences).
Cell Cycle Analysis
PANC-1 cells were transfected with either scrambled or
FKHR/FKHRL1/AFX-shRNA (FOXO-shRNA) plasmids.
FKHR/FKHRL1/AFX-shRNA (FOXO-shRNA) plasmids have
been described elsewhere [28]. Transfected cells were treated with
resveratrol (10 mM) for 24 h. Cell cycle analysis was performed as
we described elsewhere [28].
Clonogenic Assay
Pancreatic cancer cells (10
4 cells) were mixed with 0.3% agarose
and layered over a solid base of 0.5% agarose in RPMI in the
absence or presence of resveratrol in 33-mm dishes. The cultures
were incubated in humidified 5% CO2, 95% air at 37uC for 21
days and then stained with the nitro blue tetrazolium. Colonies of
.120 mm in diameter were counted using a microscope.
AKT Enzyme Assays
Cells were lysed in 1 ml of lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% (w/v) Triton X-100, 10% glycerol,
1 mM EDTA, 1 mM dithiothreitol, 1 mM benzamidine, 1 mM
phenylmethylsulfonyl fluoride, 1 mg/ml bacitracin, 1 mM
Na3VO4, 30 mM NaPPi, 10 mM NaF, 100 nM okadaic acid).
Following centrifugation, the supernatants were incubated for 2 h
at 4 uC with protein A-Sepharose beads coated with 2.5 ml of anti-
Akt antibody. Immunoprecipitates were washed three times with
the lysis buffer and twice with the kinase assay buffer (50 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol) and assayed
using GSK-3 peptide (GRPRTSSFAEG) as substrate as described
[43].
Evaluation of mRNA expression levels by quantitative
Real Time-PCR
For the quantification of gene amplification, Real-time PCR
was performed using an ABI 7300 Sequence Detection System in
the presence of SYBR- Green. Briefly, RNA isolated with or
without treatment with the chromatin modifiers using TRIzol (Life
Technologies) were reverse transcribed. cDNA reactions were
amplified with QPCR SYBR Green Mix (Applied Biosystems) and
the following gene-specific primers:
Sirt1 (59-tgt ggt aga gct tgc att ga-39,5 9- gcc tgt tgc tct cct cat ta-
39)
Sirt2 (59-aag act gtc aga gcc tgg tg-39,5 9- ata atc atc ccc agg aaa
gg-39)
Sirt3 (59-tgg aat tgg tga cct agg aa-39,5 9-acc tgt aat ccc agt tac
cc-39)
HK-GAPD (59-gag tca acg gat ttg gtc gt-39,5 9-ttg att ttg gag gga
tct cg-39)
Target sequences were amplified using incubated at 95uC for
10 min, followed by 40 cycles of 95uC for 15 s and 60uC for
1 min. HK-GAPD is used as endogenous normalization control.
All assays were performed in triplicate and were calculated on the
basis of DDCt method.
Luciferase Assay
Pancreatic cancer cell lines were transfected with empty vector,
FOXO1-TM, FOXO3a-TM or FOXO4-TM along with reporter
plasmids, p6xDBE-luc and pRL-TK [44]. The FOXO expression
vectors (wild type and phosphorylation deficient mutants) and
FOXO-luciferase constructs have been described elsewhere [44].
After 24 h, transfection medium was replaced with culture medium
and cells were treated with resveratrol (0–20 mM). After incubation
of 24 h, the relative luciferase activity, i.e. firefly enzyme activity
divided by that of the Renilla enzyme, was determined using Dual
Luciferase Reporter Assay System (Promega, Madison, WI)
according to the manufacturer’s protocol.
Electrophorectic mobility shift assay (EMSA)
FOXO probes were end-labeled with [c-
32P] dATP by
incubating oligodeoxyribonucleotide strands with 56 reaction
buffer and 10 U T4 polynucleotide kinase for 1 h at 37uC. Then
labeled oligonucleotides were allowed to anneal at room
temperature for 10 min and 20 mg protein from each sample
was used in 25 ml binding reactions, which consisted of 1 mg poly
dI-dC, in 56binding buffer (50 mM Tris HCl; pH 8.0, 750 mM
KCl, 2.5 mM EDTA, 0.5% Triton-X 100, 62.5% glycerol (v/v)
and 1 mM DTT). To determine specificity of DNA binding,
samples were incubated with or without 20 ng of unlabeled
competitor DNA for 10 min at room temperature. Then 0.1 ng of
labeled probe was added and samples were further incubated for
20 min at room temperature. Samples were separated on a 5%
non-denaturing polyacrylamide gel in 0.5% TBE and visualized
by autoradiography.
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PANC-1 (0.2610
6 cells mixed with Matrigel, Becton Dickinson,
Bedford, MA) cells in a final volume of 0.1 ml were injected into
the pancreas of Balb/c nu/nu mice (4–6 weeks old). The mice were
purchased from the National Cancer Institute, Frederick, MD.
After one week, mice (7 mice per group) were treated with
resveratrol (0, 20, 40 and 60 mg/kg body weight) through gavage
(Monday to Friday, 5 days a week for 6 weeks, once daily). At the
end of the experiment, mice were euthanized as per approved
protocol (The University of Texas Health Science Center at Tyler,
Texas), and tumors were isolated and weighed.
Immunohistochemistry
Imunohistochemistry of pancreatic cancer cells, and tumor
tissues collected on week 6 was performed as we described
elsewhere [42]. TUNEL assays were performed as per manufac-
turer’s instructions (Roche Applied Sciences).
Statistical Analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA, followed by Bonferoni’s multiple comparison tests
using PRISM statistical analysis software (GrafPad Software, Inc.,
San Diego, CA). Significant differences among groups were
calculated at P,0.05.
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